Bangkok, Thailand (PRWEB) April 19, 2006
Dr. Valentin Fulga, CEO of TheraVitae, Ltd., an international biotechnology company and the producer of VesCell™ - adult stem cell therapy for heart disease, spoke at a symposium entitled ‘Update and Advanced Management in Peripheral Arterial Disease (PAD). This seminar for medical professionals, which was sponsored by Astellas Pharma (Thailand) and TheraVitae (Thailand), was held on April 18 at Queen Sirikit National Conference Center, Bangkok, Thailand.
The opening speaker, Associate Professor Pramook Mutirangura MD, FRCST, FRCS (Edinburgh), Division of Vascular Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University; discussed ‘Introduction, Definition and Epidemiology Study of Peripheral Arterial Disease in Thai Patients’. Dr. Mutirangura is currently conducting a clinical trial using autologous adult stem cells from peripheral blood to treat severe peripheral artery disease in the lower limbs.
Also speaking, on the ‘Role of Intervention Therapy for PAD’, was Associate Professor Damras Tresukosol, MD, FRCPT Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University. Dr. Tresukosol is conducting a clinical trial using autologous adult stem cells from peripheral blood to treat angina pectoris in patients suffering from ischemic heart disease. The interim results of this trial were presented at the American Heart Association’s annual meeting in Dallas last year.
Other distinguished speakers included:
*Assistant Professor Wiwun Tungsubutra, MD, FACC, Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
*Dr. Chumpol Wongwanit, MD, FRCST, Fellow in Vascular Surgery (Sydney)
Division of Vascular Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University
This symposium was held as part of Siriraj Hospital’s commemorations of the 60th Anniversary Celebration of His Majesty’s Accession to the Throne which are taking place throughout 2006. The hospital itself was originally founded by His Majesty’s father, Prince Mahidol, who is regarded as the father of modern Thai medicine.
TheraVitae’s Public Relations Manager, Mr. Jay D. Lenner Jr., described the April 18 event as, “A great opportunity for healthcare professionals to share, gain, and spread information on the treatment of Peripheral Arterial Disease,” going on to add “Thousands suffer from undiagnosed PAD in Thailand annually. Therefore, we, at TheraVitae, are delighted to take a leading role in the symposium and would like to extend our thanks to our colleagues at Siriraj Hospital; and co-sponsors Astella Pharma (Thailand), for their support and vision in helping spread word of innovative methods of diagnosis and treatment of PAD.”
TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has already developed a proprietary stem cell technology ‘VesCell™’ that is currently being used by hospitals in Thailand to treat patients with Heart Disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, Toronto, Canada, Singapore, Taipei, Taiwan and Hong Kong.
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel
VesCell™ uses a patient's own adult stem cells to treat Heart Disease and is a viable therapeutic possibility for heart patients without any other treatment option.